{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:16:13Z","timestamp":1783199773532,"version":"3.54.6"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2022-NR067525"],"award-info":[{"award-number":["RS-2022-NR067525"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015098","name":"Seoul Metropolitan Government Seoul National University Boramae Medical Center","doi-asserted-by":"publisher","award":["2025-RISE-01-022-05"],"award-info":[{"award-number":["2025-RISE-01-022-05"]}],"id":[{"id":"10.13039\/501100015098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-25452139"],"award-info":[{"award-number":["RS-2025-25452139"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-25456722"],"award-info":[{"award-number":["RS-2025-25456722"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2024-00404555"],"award-info":[{"award-number":["RS-2024-00404555"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008130","name":"Pusan National University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118928","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T14:25:10Z","timestamp":1778423110000},"page":"118928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of RET PROTAC with excellent degradation efficiency against medullary thyroid carcinoma"],"prefix":"10.1016","volume":"315","author":[{"given":"Jaewon","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhye","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Bae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-2059","authenticated-orcid":false,"given":"Taebo","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118928_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: signalling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118928_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","article-title":"RET tyrosine kinase signaling in development and cancer","volume":"16","author":"Arighi","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2026.118928_bib3","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0092-8674(00)81311-2","article-title":"GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF","volume":"85","author":"Jing","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118928_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ejmech.2026.118928_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ejmech.2026.118928_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.118928_bib7","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1158\/0008-5472.CAN-04-2363","article-title":"RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src\/JAK\/STAT3 pathway, independent of glial cell line-derived neurotrophic factor","volume":"65","author":"Plaza Menacho","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118928_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.992636","article-title":"Precision oncology for RET-related tumors","volume":"12","author":"Verrienti","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.118928_bib9","article-title":"Research progress on RET fusion in non-small-cell lung cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.118928_bib10","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: Next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118928_bib11","doi-asserted-by":"crossref","first-page":"28929","DOI":"10.18632\/oncotarget.4325","article-title":"Identification and characterization of RET fusions in advanced colorectal cancer","volume":"6","author":"Rolle","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.118928_bib12","unstructured":"The landscape of kinase fusions in cancer | Nat. Commun., (n.d.). https:\/\/www.nature.com\/articles\/ncomms5846 (accessed February 18, 2025)."},{"key":"10.1016\/j.ejmech.2026.118928_bib13","unstructured":"RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation | Leukemia, (n.d.). https:\/\/www.nature.com\/articles\/leu2012109 (accessed February 18, 2025)."},{"key":"10.1016\/j.ejmech.2026.118928_bib14","unstructured":"RET rearrangements are actionable alterations in breast cancer | Nat. Commun., (n.d.). https:\/\/www.nature.com\/articles\/s41467-018-07341-4 (accessed February 18, 2025)."},{"key":"10.1016\/j.ejmech.2026.118928_bib15","unstructured":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial | J. Clin. Oncol., (n.d.). https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2011.35.5040 (accessed February 18, 2025)."},{"key":"10.1016\/j.ejmech.2026.118928_bib16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.118928_bib17","first-page":"9013","article-title":"A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement","volume":"34","author":"Lee","year":"2016","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2026.118928_bib18","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.jtho.2016.08.126","article-title":"Clinical activity of alectinib in advanced RET-rearranged non\u2013small cell lung cancer","volume":"11","author":"Lin","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.118928_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2026.118928_bib20","series-title":"C. for D.E. and Research, FDA Approves Selpercatinib for Medullary Thyroid Cancer with a RET Mutation","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118928_bib21","series-title":"C. for D.E. and Research, FDA Approves Selpercatinib for RET fusion-positive Thyroid Cancer","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118928_bib22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1021\/acs.jmedchem.4c02692","article-title":"Discovery of an efficacious RET PROTAC degrader with enhanced antiproliferative activity against resistant cancer cells harboring RET solvent-front mutations","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118928_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1021\/acs.jmedchem.4c01424","article-title":"Targeting oncogenic RET kinase by simultaneously inhibiting kinase activity and degrading the protein","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118928_bib24","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1021\/acs.jmedchem.4c01889","article-title":"Discovery of a selective and orally bioavailable RET degrader with effectiveness in various mutations","volume":"68","author":"Hualong","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118928_bib25","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1021\/acs.jmedchem.4c02083","article-title":"Discovery and synthesis of heterobifunctional degraders of rearranged during transfection (RET) kinase","volume":"67","author":"Qiao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118928_bib26","doi-asserted-by":"crossref","DOI":"10.1039\/D5MD00337G","article-title":"Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader","author":"Orsi","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118928_bib27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1006\/bbrc.1995.1287","article-title":"Point mutation of the RetProto-oncogene in the TT human medullary thyroid carcinoma cell line","volume":"207","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.118928_bib28","series-title":"The Tyrosine Kinase Inhibitor ZD6474 Blocks Proliferation of RET Mutant Medullary Thyroid Carcinoma Cells","author":"Vitagliano","year":"2011"},{"key":"10.1016\/j.ejmech.2026.118928_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118928_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105605","article-title":"Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy","volume":"120","author":"Shi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118928_bib31","series-title":"Brd9 Bifunctional Degraders and their Methods of Use","author":"Lorber","year":"2021"},{"key":"10.1016\/j.ejmech.2026.118928_bib32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tips.2020.02.006","article-title":"Critical assessment of targeted protein degradation as a research tool and pharmacological modality","volume":"41","author":"Kostic","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118928_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","article-title":"BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment","volume":"67","author":"Winter","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118928_bib34","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1021\/acs.jmedchem.9b00454","article-title":"De-Novo design of cereblon (CRBN) effectors guided by natural hydrolysis products of thalidomide derivatives","volume":"62","author":"Heim","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118928_bib35","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:40:41Z","timestamp":1783197641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"alternative-id":["S0223523426003739"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118928","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of RET PROTAC with excellent degradation efficiency against medullary thyroid carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118928"}}